Article Details

Imfinzi demonstrated statistically significant and clinically meaningful improvement in event ...

Retrieved on: 2024-06-25 14:20:45

Tags for this article:

Click the tags to see associated articles and topics

Imfinzi demonstrated statistically significant and clinically meaningful improvement in event .... View article details on hiswai:

Summary

The article details the positive outcomes from the NIAGARA Phase III trial on durvalumab (Imfinzi) by AstraZeneca, showcasing its effectiveness in extending event-free and overall survival for muscle-invasive bladder cancer patients. This links the epidemiology of bladder cancer to advances in oncology and the application of antineoplastic drugs.

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up